Abstract Linkage analysis is described in a family with X-linked mental retardation, ataxia, weakness, floppiness, delayed motor development, absence of deep tendon reflexes, hearing impairment and loss of vision (MIM no. 301835). The disease has a fatal course due to the susceptibility of the patients to infections, especially of the respiratory tract. Clinical signs indicate impairment of the posterior columns, peripheral motor and sensory neurons and the second and eighth cranial nerves and/or their nuclei. The involvement of the posterior columns of the spinal cord is further suggested by the almost complete absence of myelinated fibers therein. We localized the responsible gene(s) to Xq21.33-q24 between DXS1231 and DXS1001 with a maximum lod score of 6.97. The proteolipid protein gene, which codes for two myelin proteins of the central nervous system and is located in this region, was considered as a candidate gene for this disorder. However, no mutations were found in the protein-coding part of this gene.
Introduction
X-linked syndromes with mental retardation form part of the more than 120 different X-linked mental retardation conditions described so far (for review see Arena and Lubs 1991; Glass 1991; Neri 1994) . The majority of the syndromic forms of X-linked mental retardation have been assigned to specific regions of the X chromosome by cytogenetic studies and linkage analysis (Neri 1994) . A number of them have been shown to be monogenic and the gene involved has been identified, i.e., the fragile-X syndrome (Verkerk et al. 1991) , Norrie disease (Berger et al. 1992; Chen et al. 1992) , adrenoleukodystrophy (Mosser et al. 1993) , Menkes disease (Chelly et al. 1993; Mercer et al. 1993; Vulpe et al. 1993) , and DMD (Monaco et al. 1986 ). Recently, the gene coding for monoamine oxidase type A has been identified as the cause of mental impairment with behavioral disturbance (Brunner et al. 1993) . Other syndromes might be contiguous gene syndromes.
We performed linkage analysis in a family with a syndromic developmental delay, previously described by Arts et al. (1993; MIM no. 301835 , Fig. 1 ). Patients show a combination of a number of the following symptoms: mental retardation, an early onset floppiness, weakness, ataxia, deafness, delayed motor development, nystagmus, loss of vision and susceptibility to infections, especially of the respiratory tract. Flaccid tetraplegia and areflexia appear later. Infections were the cause of death before the age of 6 years in 11 of 12 boys. The oldest patient, now 16 years of age, has become nearly blind owing to optic atrophy and lives in an institute for the visually and mentally handicapped. Clinical signs indicate impairment of the posterior columns, peripheral motor and sensory neurons and the second and eighth cranial nerves and/or nuclei. The central nervous system (CNS) of one patient could be examined at autopsy. In the posterior columns of the spinal cord, myelin was found to be almost completely absent whereas no abnormalities were seen in the brainstem and in the gray and white matter of the cerebral and cerebellar hemispheres. A number of dorsal nerve roots that could be examined showed the same abnormalities as the posterior columns. Biochemical or immunological defects could not be detected in patients. Carriers may suffer from perceptive hearing loss, ataxic diplegia, extensor plantar reflexes, hypotonia, hyperreflexia or low deep tendon reflexes.
Linkage analysis has enabled us to assign regionally the gene(s) responsible for this condition to Xq21.33-q24, between the markers DXS1231 and DXS1001. Localization of the gene (or genes) for a syndrome with X-linked mental retardation, ataxia, weakness, hearing impairment, loss of vision and a fatal course in early childhood Fig. 1 Pedigree of the family described by Arts et al. (1993) . Only the part from which blood samples were available has been depicted. The cosegregating region is marked with a bar
Materials and methods

Analysis of DNA markers
For the typing of the DNA markers, genomic DNA was isolated from peripheral blood according to the method of Miller et al. (1988) . Fifty nanograms of genomic DNA was amplified in a 15 µl reaction mixture containing 1 × Supertaq buffer [10 mM TRISHCl, pH 9.0, 50 mM KCl, 1.5 mM MgCl 2 , 0.1% Triton X-100, 0.01% (w/v) gelatin], 200 µM each of dATP, dGTP, dTTP and 2.5 µM dCTP, 0.6 µCi [α 32 P]dCTP (10 mCi/ml, 3000 Ci/mmol), and 0.06 U Supertaq (HT Biotechnology, England). The initial denaturation of 5 min at 94°C was followed by 35 cycles of 94°C for 1 min, 55°C for 2 min and 72°C for 3 min. After the cycles there was a final extension of 6 min at 72°C (method modified from Weber and May 1989) . Amplification was performed in a 96-well thermal cycler (M. J. Research). Samples were analyzed on a 6.6% polyacrylamide gel (19 :1 acrylamide:N,N′-methylene bisacrylamide) containing 8.3 M urea, 1 × TBE (100 mM TRIS-borate, 2 mM EDTA, pH 8.3) at 60 W for 3-4 h. The gels were dried and bands were visualized by overnight exposure on Kodak X-OMAT S film.
Sequence analysis
Amplification of the exons of the proteolipid protein (PLP) gene by the polymerase chain reaction was performed as described by Gencic et al. (1989) . Fragments were cycle sequenced and analyzed on an ABI 373 automatic sequencer, according to the protocol of the manufacturer (ABI, Forster City, USA).
Statistical analyses
Linkage data were evaluated with the subroutine Mlink of the Linkage program (version 5.1; Lathrop and Lalouel 1984) . Complete penetrance and a frequency of 0.00001 for the disease allele were assumed for the calculations. The locations of the markers, their genetic distances and allelic frequencies were used as given by Nelson et al. (1995) and the Genome Data Base.
Results and discussion
The family with an X-linked mental retardation syndrome (Arts et al. 1993) was analyzed for cosegregation with a set of highly polymorphic markers from loci distributed along the entire X chromosome. The results of two-point linkage analysis are summarized in Table 1 .
No recombination was found for the marker loci distal to DXS1231 and proximal to DXS1001 (Fig. 1, Table 1 ) with a maximal lod score of 6.97, θ max = 0.00 for the marker DXS1106. There was no indication for linkage with markers from other parts of the X chromosome. Thus, the X-linked mental retardation gene (or genes) responsible for the disease in the present family can be assigned to the Xq21.33-q24 interval between DXS1231 and DXS1001, which has an estimated length of about 20 Mb (Nelson et al. 1995) .
The PLP gene, which encodes two major components of the CNS myelin, PLP and DM20 (Nave et al. 1987) , is located in Xq22.1 (Mattei et al. 1986) , and is thus within the interval to which the present syndrome has been assigned. Mutations in the PLP gene have been found in a number of patients with Pelizaeus-Merzbacher disease (PMD, MIM no. 312080), an X-linked disorder with dysmyelination of the cerebral white matter Hudson et al. 1989; Trofatter et al. 1989 ). In addition, mutations in the PLP gene have been described in families with X-linked spastic paraplegia type 2 (SPG2; MIM no. 312900; Saugier-Veber et al. 1994 ). SPG2 shares several clinical features with PMD including nystagmus, cerebellar ataxia and pyramidal syndrome. Dysmyelination was also observed in one of the patients described here, but it was confined to the posterior columns of the spinal cord. Besides dysmyelination, symptoms common to the present syndrome and PMD/SPG2 are mental retardation, hypotonia, nystagmus, optic atrophy and abnormal brainstem and somatosensory evoked potentials. The present syndrome and PMD/SPG2 differ with respect to peripheral nerve involvement, hearing defect and the recurrent infections that occur only in the present X-linked mental retardation syndrome, whereas pyramidal and extrapyramidal signs, microcephaly and laryngeal stridor, which are characteristics of PMD/SPG2, are not observed. Despite these differences, the common symptoms suggest that PLP is a candidate gene for the present syndrome.
To screen the PLP gene for the presence of a mutation we directly sequenced the seven exons of the PLP gene of one of the patients (Diehl et al. 1986) . No indications for mutations in the translated regions of the PLP gene were detected. However, a mutation might be present in the regulatory sequences, which were not analyzed. PMDlike clinical features have also been described in a patient with a duplication of the PLP gene (Cremers et al. 1987; cf. Ellis and Malcolm 1994) . To rule out the possibility that in our family too, the disorder is due to gene duplication, the copy number of the PLP gene was tested in two patients. Hereby we excluded that the present syndrome is due to amplification of the PLP gene in the affected males.
The syndrome described in this study resembles the Xlinked mental retardation with aphasia described by Wilson et al. (1992) . Linkage analysis in the family with the latter disorder does not exclude the region between DXS1231 and DXS1001. Patients suffer from hypotonia and frequent infections especially of the respiratory tract, which is also typical of the present mental retardation syndrome. Furthermore, delayed myelination was shown by MRI scanning of one of the patients. This overlap in symptoms might indicate allelism of both disorders or they might be contiguous gene syndromes. Of the other X-linked mental retardation conditions that have been assigned to a region overlapping with that of the present disorder (see Neri 1994) , there is some clinical resemblance with the Mohr-Tranebjaerg syndrome (MIM no. 304700, Tranebjaerg et al. 1995) regarding ataxia, psychomotor development, deafness and visual impairment. A more detailed mapping and, eventually, candidate gene analysis is necessary to give insight into the question of the allelism or overlap of genes involved in the described syndromes. Clinically, the present condition has most features in common with the infantile X-linked ataxia and deafness syndrome described by Schmidley et al. (1987; MIM no. 301790) . However, since the latter condition has not been assigned to a specific region of the X chromosome, no conclusions can be drawn concerning allelism or overlap of a gene (or genes) involved in both syndromes.
Despite our inability to find mutations or duplications of the PLP gene, a role of this gene in the etiology of the syndrome we studied cannot be ruled out until analysis of the regulatory sequences of the gene in patients with the present syndrome has been completed. Exclusion of allelism of the present syndrome and those resembling it clinically awaits further mapping studies. 
